Ag270 clinical
WebFor research use only. AG-270 is a potent and non-competitive methionine adenosyltransferase 2A (MAT2A) inhibitor which lessens the intracellular SAM levels and MTAP-null–selective antiproliferative activity. CAS No. 2201056-66-6. The item is temporarily out of stock. Please leave your email address and we will inform you when …
Ag270 clinical
Did you know?
WebAbout this study The purpose of this study is to determine the maximum tolerated dose (MTD) of AG-270 and characterize its dose-limiting toxicities (DLTs) when given daily by … WebOct 27, 2024 · AG-270 is a first-in-class, oral, potent, reversible inhibitor of methionine adenosyltransferase 2A (MAT2A), the key enzyme responsible for SAM synthesis. …
WebAug 15, 2024 · We have developed a first-in-class small molecule inhibitor of MAT2A, AG-270, currently in a phase 1 clinical study (ClinicalTrials.gov NCT03435250) for the treatment of patients with solid tumors ... WebAG-270 demonstrates potent reduction in levels of intracellular SAM, as well as MTAP-null–selective antiproliferative activity in the HCT116 MTAP isogenic cell model in vitro[1]. …
WebCAMBRIDGE, Mass., Oct. 09, 2024 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that results from the single agent dose-escalation portion of the ongoing Phase 1 study of AG-270 in patients with MTAP-deleted tumors and the pre-clinical translational … WebApr 8, 2024 · On the basis of these discoveries, AG-270, an oral, first-in-class MAT2A inhibitor, has entered clinical development and is under investigation in a phase 1 trial …
WebOct 27, 2024 · expectations for its and its collaborator’s preclinical, clinical and commercial advancement of its drug development programsincluding AG-270; the potential benefits …
WebDec 1, 2024 · AG-270 is a first-in-class, oral, potent, reversible inhibitor of methionine adenosyltransferase 2A (MAT2A), the key enzyme responsible for SAM synthesis. We … employee offers btWebOct 9, 2024 · AG-270 is an investigational, first-in-class methionine adenosyltransferase 2a (MAT2A) inhibitor. The schedule for the presentations is as follows: Title: A Phase 1 trial … drawbacks of machine guns in ww1WebJul 29, 2024 · History of Changes for Study: NCT03435250 Study of AG-270 in Subjects With Advanced Solid Tumors or Lymphoma With MTAP Loss Latest version (submitted July 29, 2024) on ClinicalTrials.gov A study version is represented by a row in the table. Select two study versions to compare. One each from columns A and B. drawbacks of mendeleev periodic tableWebA powerful approach We are leveraging the genetic principle of synthetic lethality and the power of our state-of-the-art CRISPR-based target discovery engine to discover and validate multiple novel targets each year. Our growing pipeline consists of programs for genetically defined subsets of cancers with limited treatment options. drawbacks of marble countertopsWebApr 12, 2024 · Based on density functional theory, the ground state and magnetic order of monolayer AgCr 2 S 4 have been determined. The centrosymmetry emerges upon two-dimensional confinement and thus eliminates the bulk polarity. Moreover, two-dimensional ferromagnetism appears in the CrS 2 layer of AgCr 2 S 4 and can persist up to room … drawbacks of long term care insuranceWebApr 8, 2024 · We demonstrate that potent MAT2A inhibitors substantially reduce SAM levels in cancer cells and selectively block proliferation of MTAP -null cells both in tissue culture … drawbacks of mergers and acquisitionsWebFeb 1, 2024 · AG-270 in Combination with Docetaxel a. Be ≥18 years of age; a. Have histologically confirmed diagnosis of non-small cell lung cancer (NSCLC) that has been treated with no more than 2 prior lines of cytotoxic chemotherapy in the setting of metastatic (Stage 4) disease. drawbacks of market penetration